The global chemiluminescence immunoassay market was valued at USD 6.2 billion in 2019 and is expected to grow at a CAGR of 7.2% during the forecast period. The factors responsible for the growth of chemiluminescence immunoassay market are the rising prevalence of chronic diseases, industry-academia collaboration, and the introduction of technologically advanced automated systems. These immune-assay solutions are rapidly used in chronic conditions such as diabetes, autoimmune and infectious diseases, obesity, cancer, and cardiovascular disorders.
Chemiluminescence immune-assay systems are being used by research institutes, academic institutions, and pharmaceutical companies for the therapeutic monitoring. Thus, early diagnosis of diseases, and rising drug discovery activities by the pharma companies are, also boosting the sales of CLIA systems.
Know more about this report: request for sample pages
Chemiluminescence immunoassay techniques are widely regarded as gold standard in the detection of several chronic diseases such as neurological disorders, infectious diseases, auto-immune disorders, cancer, and heart related ailments, which in turn is expected to drive the sale of chemiluminescence immunoassay solutions across the globe. According to the statistics published by Globocan, in 2018, approximately 18 million new cases of cancer were detected, across the globe. American Diabetes Association also predicted in the same year more than 34.2 million people in the U.S. are having diabetes or related co-morbidity. Moreover, according to the estimates of WHO, as of May, around 4.3 million individuals around were suffering with COVID-19. Such, recent spike in COVID-19 maximized the demand for such systems for diagnosis, thus driving the chemiluminescence immunoassay systems in the market.
Moreover, the major players in the chemiluminescence immunoassay market are focused on developing technologically advanced assay systems. For instance, in August 2018, China-based Mindray Medical manufacturer introduced new CL900i immune-assay system. In August 2020, another major player, DiaSorin received emergency use authorization for the LIAISON SARS-CoV-2 S1/S2 IgG test. This was launched, in response to the rapid spike in the COVID-19 cases across the regions. The introduction of such novel systems is expected to drive the demand for chemiluminescence immunoassay systems.
The market is primarily segmented on the basis of product, application, end-use, and region.
Know more about this report: request for sample pages
The global chemiluminescence immunoassay product segment is categorized into consumables, instruments, and software & services. In 2019, consumables segment dominated the market and is likely to maintain its dominance over the projected period. This high share is attributed to the high demand and usage of consumables in assay procedure. Within the segment, automated systems accounted for the highest revenue share owing to its high speed and efficiency.
The instrument market segment is projected to register fastest growth rate in the chemiluminescence immunoassay industry. This growth is anticipated due to introduction of dedicated advanced systems for the immunoassays. For instance, in August 2017, the key player in the market, Beckman Coulter, launched Access 2 immunoassay system improved version. The system provides user friendliness, workflow efficiencies, and reliability.
In 2019, infectious diseases segment accounted for the highest revenue share. The introduction of robust chemiluminescence immunoassay systems for infectious diseases by the major players in the marketplace were responsible for the segment’s growth. In line with this, in September 2018, DiaSorin in partnership with Qiagen introduced LIAISON QuantiFERON-TB Gold Plus assay, purely dedicated for the diagnosis of Tuberculosis.
Oncology segment is projected to exhibit highest growth rate over the chemiluminescence immunoassay industry forecast period. This future growth is due to the rise in medical attention of the patients in the middle-income countries and rising cancer mortality. According to the estimates of World Health Organization (WHO), cancer mortality cases occur more in the low and middle-income countries.
North America market is the largest revenue contributor in the global chemiluminescence immunoassay industry and is expected to maintain its dominance over the projected period. Presence of key players with well-developed distribution network, adoption of automated systems, and rising cases of chronic problems are the key factors responsible for the region’s growth. Moreover, the presence of local players in the U.S. such as Roche, Abbott Laboratories, and DiaSorin further increases the accessibility of these chemiluminescence immunoassay systems in the market.
Asia Pacific is projected to grow at the highest growth rate over the forecast period. Two most populated countries India and China, with increasing medical awareness and booming middle class economy have attracted the attention of major players operating in the market. In line with this, to take advantage of such fruitful situation, the global companies in chemiluminescence immunoassay industry are bound to increase their presence. For instance, in 2018, China based, Shenzhen Mindray, introduced CL-6000i CLIA analyzer.
Key market players operating in the global chemiluminescence immunoassay industry include DiaSorin S.p.A., F. Hoffmann-La Roche AG, Abbott Laboratories, Immunodiagnostic Systems, Maccura Biotechnology Co., Ltd., Shenzhen Mindray, Beckman Coulter Inc., Siemens Healthineers, Inova Diagnostics, Inc., and Ortho Clinical Diagnostics.
The major players in the market are focusing on exclusive collaborations, partnerships, and agreements to stay competitive in the market. For instance, in April 2020, Accelerate Diagnostics and BioCheck, Inc. signed distribution agreement for the immunoassay systems. According to the terms of the agreement, Accelerate, will distribute the BioCheck’s automated systems, and also its SARS-CoV-2 test kits to detect IgM and IgG antibodies.